1. Osteoactivin expression is required for the invasive phenotype of in vivo selected bone metastatic 4T1 breast cancer cells.
Osteoactivin expression is required for the invasive phenotype of in vivo selected bone metastatic 4T1 breast cancer cells. A. Seventy-two hours posttransfection, immunoblot analyses were done on control and osteoactivin (OA) siRNA–transfected 592 and 593 BM2 cells, using antibodies against osteoactivin (top), MMP-3 (middle), and α-tubulin (bottom; data not shown for 593 BM2 cells). B. Motility (top) and invasion (bottom) assays were done as described in Fig. 3. Significant differences in invasion were observed between 592 and 593 BM2 cells treated with osteoactivin siRNAs compared with 592 and 593 BM2 cells treated with control siRNAs (*, P < 0.01; **, P < 0.03). Results are derived from at least three independent experiments. C. Representative images are shown for both motility (top) and invasion (bottom). D. Quantitative real-time PCR analysis was done to examine MMP-3 expression in the in vivo selected bone metastatic populations compared with parental 4T1 cells. MMP-3 expression was first normalized to GAPDH levels and expressed as the fold change over 4T1 parental cells.
April A.N. Rose et al. Mol Cancer Res 2007;5:
©2007 by American Association for Cancer Research